IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
The properties of tumor-initiating cells from a hepatocellular carcinoma patient′s primary and recurrent tumor
Xu, Xiao-Lan1,2; Xing, Bao-Cai3; Han, Hai-Bo1; Zhao, Wei1; Hu, Mei-Hao2; Xu, Zuo-Liang1; Li, Ji-You4; Xie, Yong5; Gu, Jun2; Wang, Yu1; Zhang, Zhi-Qian1
刊名CARCINOGENESIS
2010-02-01
DOI10.1093/carcin/bgp232
31期:2页:167-174
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]CANCER STEM-CELLS ; B-VIRUS DNA ; POLY(ADP-RIBOSE) POLYMERASE ; LIVER-CANCER ; ALDEHYDE DEHYDROGENASE ; STEM/PROGENITOR CELLS ; GENE-EXPRESSION ; SIDE POPULATION ; INHIBITORS ; TUMORIGENICITY
英文摘要

Hepatocellular carcinoma (HCC) is associated with a high morbidity and mortality due to its high rate of recurrence. However, little is known about the biological characteristics of recurrent HCC cells. A single patient′s primary and recurrent HCC-derived cell lines, Hep-11 and Hep-12, respectively, were established by primary culture. These two cell lines have the same hepatitis B virus integration site and share many common amplifications and deletions, which suggest that they have the same clonal origin. While Hep-11 cells were non-tumorigenic at 16 weeks following injection of up to 10 000 cells, injection of only 100 Hep-12 cells was sufficient to initiate tumor growth, and all single Hep-12 clones were tumorigenic in immunodeficient mice. Compared with Hep-11, Hep-12 cells expressed the oval cell markers AFP, NCAM/CD56, c-kit/CD117, as well as multiple stem cell markers such as Nanog, OCT4 and SOX2. In addition, > 90% of Hep-12 cells were aldehyde dehydrogenase positive. They were also less resistant to paclitaxel, but more resistant to doxorubicin, cisplatin and hydroxycamptothecin (HCPT), which had been administrated to the patient. Furthermore, Hep-12 cells expressed higher levels of poly (adenosine diphosphate-ribose) polymerase-1 (PARP-1) than Hep-11, and PARP-1 inhibition potentiated the sensitivity to HCPT in Hep-12 cells but not in Hep-11 cells. These results indicate that a large population of the recurrent HCC-derived Hep-12 cells were tumor-initiating cells and that elevated expression of PARP-1 was related to their resistance to HCPT.

语种英语
WOS记录号WOS:000274088300004
项目编号30670413 ; 30671060 ; 2010CB529402 ; NCET-07-0031
资助机构National Natural Science Foundation of China ; National Basic Research Program of China ; Program for New Century Excellent Talents in University of China
引用统计
被引频次:51[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/65122
专题北京大学临床肿瘤学院
北京大学临床肿瘤学院_肝胆胰外一科
北京大学临床肿瘤学院_603课题组
作者单位1.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst,Dept Cell Biol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
2.Peking Univ, Inst Life Sci, Natl Key Lab Prot Engn & Plant Gene Engn, Beijing 100871, Peoples R China
3.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Hepatobiliary Surg 1, Beijing 100142, Peoples R China
4.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Pathol, Beijing 100142, Peoples R China
5.Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Hong Kong, Peoples R China
推荐引用方式
GB/T 7714
Xu, Xiao-Lan,Xing, Bao-Cai,Han, Hai-Bo,et al. The properties of tumor-initiating cells from a hepatocellular carcinoma patient′s primary and recurrent tumor[J]. CARCINOGENESIS,2010,31(2):167-174.
APA Xu, Xiao-Lan.,Xing, Bao-Cai.,Han, Hai-Bo.,Zhao, Wei.,Hu, Mei-Hao.,...&Zhang, Zhi-Qian.(2010).The properties of tumor-initiating cells from a hepatocellular carcinoma patient′s primary and recurrent tumor.CARCINOGENESIS,31(2),167-174.
MLA Xu, Xiao-Lan,et al."The properties of tumor-initiating cells from a hepatocellular carcinoma patient′s primary and recurrent tumor".CARCINOGENESIS 31.2(2010):167-174.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Xu, Xiao-Lan]的文章
[Xing, Bao-Cai]的文章
[Han, Hai-Bo]的文章
百度学术
百度学术中相似的文章
[Xu, Xiao-Lan]的文章
[Xing, Bao-Cai]的文章
[Han, Hai-Bo]的文章
必应学术
必应学术中相似的文章
[Xu, Xiao-Lan]的文章
[Xing, Bao-Cai]的文章
[Han, Hai-Bo]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。